The interview is available via on-demand at PharmaTelevision beginning Wednesday, September 5, 2012 and also will be available to the public at the Aptalis Pharmaceutical Technologies website.

Fraher serves a key role in setting strategic direction for Aptalis with specific oversight of the company’s Pharmaceutical Technologies and Global Supply Chain business unit. PharmaTelevision is an online TV channel for the biopharma industry offering feature interviews with industry leaders, analysis and a television news archive.

Visit www.AptalisPharmaTech.com

Approximately one year ago PharmaTelevison conducted its first interview with Fraher just a few months after Axcan completed its acquisition of Eurand N.V. During the months following the acquisition, the companies completed their integration while realizing several major milestones including FDA approvals, the in-licensing of a number of products and a closing-year revenue of $470 million – a significant increase on the prior year. During his BIO 2012 interview with PharmaTelevision, Fraher discusses these milestones and the company’s strategic direction moving forward.

^{About PharmaTelevision
PharmaTelevision® is the groundbreaking online TV channel for the biopharma industry offering feature interviews with industry leaders, analysis and a television news archive. Established in 2006, the channel now boasts a global audience of 10,000+ viewers including top industry executives. PharmaTelevision is produced by professional television industry experts using professional studios worldwide as well as its own studios in Oxford, England.}